This content was selected by and is provided to you courtesy of Your Company.
2750 Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)
Video
Abstract
V. Mueller1, E. Paplomata2, E.P. Hamilton3, A. Zelnak4, L. Fehrenbacher5, E.H. Jakobsen6, E. Curtit7, F. Boyle8, E.H. Brix9, A.J. Brenner10, C. Ferrario11, M. Munoz-Mateu12, T. Arkenau13, K.A. Gelmon14, D. Cameron15, G. Curigliano16, K. DeBusk17, J. Ramos18, X. An19, A.M. Wardley20
Show/Hide Author Information
Author affiliations
- 1 Gynecology, University Medical Center Hamburg-Eppendorf, 20246 – Hamburg/DE
- 2 Internal Medicine, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, 53792 – Madison/US
- 3 Breast Oncology, Sarah Cannon Research Institute-Cancer Center, 37203 – Nashville/US
- 4 Atlanta Cancer Care, Northside Hospital, Sandy Springs/US
- 5 Oncology, Kaiser Foundation Research Institute, 94612 – Oakland/US
- 6 Dept. Of Oncology, Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, 7100 – Syddanmark/DK
- 7 Medical Oncology, University Hospital of Besançon, 25000 – Besançon/FR
- 8 Patricia Ritchie Centre, Mater Hospital, 2060 – North Sydney/AU
- 9 Oncology, Herlev Hospital, 2730 – Herlev/DK
- 10 Hematology And Medical Oncology, Mays Cancer Center at the UT Health San Antonio, 78229-3264 – San Antonio/US
- 11 Oncology, Jewish General Hospital McGill University, H3T 1E2 – Montreal/CA
- 12 Medical Oncology, Hospital Clinic I Provincial de Barcelona, 08036 – Barcelona/ES
- 13 Drug Development Program, Sarah Cannon Research Institute UK and University College London Cancer Institute, WG 6AD – London/GB
- 14 Medical Oncology, British Columbia Cancer Agency – Vancouver Centre, V5Z 4E6 – Vancouver/CA
- 15 Edinburgh Cancer Research Centre, IGMM, University of Edinburgh, EH4 2RU – Edinburgh/GB
- 16 Oncology And Hemato-oncology, European Institute of Oncology, IRCCS and University of Milano, 20141 – Milan/IT
- 17 Heor, Seattle Genetics, Inc., 98021 – Bothell/US
- 18 Clinical Development Dept., Seattle Genetics, Inc., 98021 – Bothell/US
- 19 Biostatistics, Seattle Genetics, Inc., Bothell/US
- 20 Medical Oncology, The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation & Trust Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, M20 4BX – Manchester/GB
Disclosure
V. Mueller: Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution): AstraZeneca; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (institution), Advisory/Consultancy: Eisai; Honoraria (institution): Genomic Health; Honoraria (institution), Advisory/Consultancy: Lilly; Honoraria (institution): MSD Oncology; Honoraria (institution), Advisory/Consultancy: Nektar; Honoraria (institution), Research grant/Funding (institution): Novartis; Honoraria (institution): Pierre Fabre; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics; Honoraria (institution): Tesaro; Honoraria (institution): Teva; Advisory/Consultancy: Hexal; Research grant/Funding (institution): Roche/Genentech; Travel/Accommodation/Expenses: Pfizer. E. Paplomata: Honoraria (institution), Advisory/Consultancy: Mylan; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (institution), Advisory/Consultancy: R-Pharm; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Cascadian Therapeutics; Research grant/Funding (institution): Corcept Therapeutics; Research grant/Funding (institution), Travel/Accommodation/Expenses: Genentech; Research grant/Funding (institution): Hoosier Cancer Research Network; Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck; Research grant/Funding (institution): Seattle Genetics; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: Tesaro. E.P. Hamilton: Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): AceraPharma; Research grant/Funding (institution): Aravive; Research grant/Funding (institution): ArQule; Research grant/Funding (institution), Travel/Accommodation/Expenses: Arvinas; Advisory/Consultancy, Research grant/Funding (institution), Advisory/Consultancy paid to institution only: AstraZeneca; Research grant/Funding (institution): BerGenBio; Advisory/Consultancy, Research grant/Funding (institution), Advisory/Consultancy paid to institution only: Black Diamond Therapeutics; Advisory/Consultancy, Research grant/Funding (institution), Advisory/Consultancy paid to institution only: Boehriner Ingelheim; Research grant/Funding (institution): Clovis Oncology; Research grant/Funding (institution): Compugen; Research grant/Funding (institution): Curis; Research grant/Funding (institution): CytomX Therapeutics; Advisory/Consultancy, Research grant/Funding (institution), Advisory/Consultancy paid to institution only: Daiichi Sankyo; Research grant/Funding (institution): Deciphera; Research grant/Funding (institution): eFFECTOR Therapeutics; Research grant/Funding (institution), Travel/Accommodation/Expenses: Eisai; Research grant/Funding (institution), Travel/Accommodation/Expenses: EMD Serono; Research grant/Funding (institution): Fochon Pharma; Research grant/Funding (institution): Fosun Orinove; Research grant/Funding (institution): Fujifilm; Research grant/Funding (institution): G1 Therapeutics; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Advisory/Consultancy paid to institution only: Genentech/Roche; Research grant/Funding (institution): H3 Biomedicine; Research grant/Funding (institution): Harpoon; Research grant/Funding (institution): Hutchison MediPharma; Research grant/Funding (institution): Immunigenics; Research grant/Funding (institution): InventisBio; Research grant/Funding (institution): Karyopharm Therapeutics; Research grant/Funding (institution): Leap Therapeutics; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Advisory/Consultancy paid to institution only: Lilly; Research grant/Funding (institution): Lycera; Research grant/Funding (institution): Macrogenics; Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): Mediation; Research grant/Funding (institution), Advisory/Consultancy paid to institution only: Mersana; Research grant/Funding (institution): Merus; Research grant/Funding (institution): Millennium; Research grant/Funding (institution): Molecular Templates; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Advisory/Consultancy paid to institution only: Novartis; Research grant/Funding (institution): Nucana; Shareholder/Stockholder/Stock options: OncoMed; Research grant/Funding (institution), Travel/Accommodation/Expenses, Advisory/Consultancy paid to institution only: Pfizer; Advisory/Consultancy, Research grant/Funding (institution), Advisory/Consultancy paid to institution only: PumaBiotech; Research grant/Funding (institution): Radius Health; Research grant/Funding (institution): Regeneron; Research grant/Funding (institution): Rgenix; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): Sermonix Pharma; Advisory/Consultancy, Research grant/Funding (institution), Advisory/Consultancy paid to institution only: Silverback Therapeutics; Research grant/Funding (institution): Stem CentRx; Research grant/Funding (institution): Sutro Biopharma; Research grant/Funding (institution): Syndax; Research grant/Funding (institution): Syrol Pharma; Research grant/Funding (institution): Taiho Pharma; Research grant/Funding (institution): Takeda; Research grant/Funding (institution), Travel/Accommodation/Expenses: Tesaro; Research grant/Funding (institution): Unum Therapeutics; Research grant/Funding (institution): Verastem; Research grant/Funding (institution): Zenith Epigenetics; Research grant/Funding (institution): Zymeworks; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: Bayer; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: Clovis Oncology; Travel/Accommodation/Expenses: Foundation Medicine; Travel/Accommodation/Expenses: Genzyme; Travel/Accommodation/Expenses: Guardant Health; Travel/Accommodation/Expenses: Helsinn Therapeutics; Travel/Accommodation/Expenses: Heron; Travel/Accommodation/Expenses: Medivation; Travel/Accommodation/Expenses: Merck; Travel/Accommodation/Expenses: Sysmex. A. Zelnak: Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Travel/Accommodation/Expenses: Immunomedics. E.H. Jakobsen: Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Roche; Advisory/Consultancy: Lilly. F. Boyle: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Eli Lilly; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis. E.H. Brix: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Pierre Fabre. A.J. Brenner: Advisory/Consultancy, Leadership role, Shareholder/Stockholder/Stock options, intellectual property interest: NanoTX; Advisory/Consultancy, Shareholder/Stockholder/Stock options: Plus Therapeutics; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Vascular Biogenics; Advisory/Consultancy: Alamab Therapeutics; Research grant/Funding (self): Threshold Pharmaceuticals; Research grant/Funding (institution): miRNA Therapeutics; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): Upshaw Smith; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution): Medicenna. T. Arkenau: Full/Part-time employment: HCAHealthcare UK; Full/Part-time employment: Sarah Cannon; Advisory/Consultancy: Roche; Advisory/Consultancy: Beigene; Advisory/Consultancy: Bicycle; Advisory/Consultancy: iOnctura; Advisory/Consultancy: Bayer; Advisory/Consultancy: Servier; Advisory/Consultancy: Biontech. K.A. Gelmon: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy: Genentech; Advisory/Consultancy: Genomic Health; Advisory/Consultancy: Janssen Oncology; Advisory/Consultancy: Lilly; Advisory/Consultancy: Merck; Advisory/Consultancy: Mylan; Advisory/Consultancy: NanoString Technologies; Advisory/Consultancy: Novartis; Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Roche. D. Cameron: Advisory/Consultancy, Research grant/Funding (institution): GlaxoSmithKlein; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy: Synthon; Research grant/Funding (institution): Seattle Genetics; Full/Part-time employment: Edinburgh Cancer Research Centre; Full/Part-time employment: Edinburgh UK. G. Curigliano: Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): Ellipsis; Full/Part-time employment: University of Milano, Istituto Europeo di Oncologia, IRCCS, Milan, Italy. K. DeBusk: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics; Shareholder/Stockholder/Stock options: Roche. J. Ramos: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics. X. An: Shareholder/Stockholder/Stock options, Full/Part-time employment: Seattle Genetics; Full/Part-time employment: Novartis. A.M. Wardley: Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eli Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Athenex; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy: Gerson Lehrman Group; Honoraria (self), Advisory/Consultancy: Guidepoint Global; Honoraria (self): Coleman Expert Network; Honoraria (self): Helios; Honoraria (self): Health Care America; Advisory/Consultancy, Research grant/Funding (institution): Accord Research; Advisory/Consultancy: NAPP Pharma; Speaker Bureau/Expert testimony: Eisai; Leadership role, Research grant/Funding (self): NIHR Manchester Clinical Research Facility at The Christie Strategy Director for Association of Cancer Physicians ; Leadership role: Committee Member UK Breast Cancer Group; Leadership role: Committee Member NHS England Chemotherapy Clinical Reference Group; Leadership role: ESMO Breast cancer faculty; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): IGI Therapeutics; Shareholder/Stockholder/Stock options, Officer/Board of Directors, Spouse/Financial dependant: Andrew Wardley Limited; Shareholder/Stockholder/Stock options, Officer/Board of Directors: Manchester Cancer Academy; Shareholder/Stockholder/Stock options, Officer/Board of Directors: Outreach Research & Innovation Group Limited; Full/Part-time employment: NIHR Manchester Clinical Research Facility at The Christie; Advisory/Consultancy: Coleman Research. All other authors have declared no conflicts of interest.
Background: Patients (pts) with human epidermal growth factor receptor 2 positive (HER2+) MBC, particularly pts with BM, have limited treatment (tx) options and increased likelihood to report deterioration in HRQoL. Maintaining QoL in pts with MBC who progress through different lines of therapy is an important outcome in clinical trials. In the HER2CLIMB (H2C) study, tucatinib (TUC) + trastuzumab (T) + capecitabine (C) demonstrated statistically significant improvement in progression free survival (PFS) and overall survival (OS) over T + C alone. In HER2+ MBC pts with and without BM, TUC + T + C had a manageable safety profile similar to T + C alone. Here we report the impact of TUC on HRQoL, a secondary objective in H2C.
Methods: Assessment of HRQoL was initiated with protocol version 7, using the EQ-5D-5L which includes a EQ visual analog scale (EQ-VAS) and descriptive system (EQ-5D) of 5 health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no, slight, moderate, severe, or extreme problems. Data were available from 330 of 612 pts and were collected at Cycles (C) 1, 3-9 (every 2 C; 21 day C), C 12 and beyond (every 3 C), and at 30 day follow-up. TUC and placebo group EQ-5D-5L scores were calculated for each dimension and summarized. HRQoL pt reported outcomes were evaluated using longitudinal and descriptive data analyses.
Results: In H2C, data from 217 pts on the TUC arm and 113 pts on the placebo arm were available for HRQoL analyses. In all 5 EQ-5D-5L domains, most pts in both arms reported only slight or no problems. Reported moderate, severe, or extreme problems were low and similar between tx arms. No clinically meaningful differences in HRQoL were observed between tx arms. Mean EQ-5D-5L VAS scores were similar between tx arms and stable throughout duration of therapy. Decline on EQ-5D-5L domains and VAS scores were not seen while pts were on therapy. All available QoL data will be presented.
Conclusions: In H2C, addition of TUC resulted in statistically significant and clinically meaningful improvement in PFS and OS. Moreover, QoL in pts treated with TUC + T + C was maintained throughout the tx period which was longer compared to pts receiving only T + C.
Clinical trial identification: NCT02614794.
Editorial acknowledgement: Medical writing assistance was funded by Seattle Genetics, Inc., and provided by Aulma Parker, PhD, of Seattle Genetics, Inc.
Legal entity responsible for the study: Seattle Genetics.
Funding: Seattle Genetics.
Slides
Proffered Paper
© Copyright 2020 European Society for Medical Oncology (ESMO). All rights reserved.
Meeting: ESMO Virtual Congress 2020
Presenter: Volkmar Mueller
Presentation Date: September 21, 2020
Abstract Number: 2750
Disclaimer
© Copyright 2020 European Society for Medical Oncology (ESMO). All rights reserved.
This selection of Meeting presentations was made by Your Company and ESMO did not participate in the selection. This selection of presentations does not necessarily represent a balanced view or full discussion of any given subject. Any summaries or commentary appearing herein were not prepared or reviewed by ESMO. The ideas and opinions expressed herein do not necessarily reflect the views of ESMO or Springer Healthcare.
The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ESMO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ESMO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.
Site provided by Springer Healthcare Limited. Part of the Springer Nature Group.
